title: Novel targeted therapies in diffuse large B-cell lymphoma.
abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma. Next-generation sequencing techniques have improved our understanding of the molecular pathways that may drive oncogenesis. Many novel classes of drugs are in development that may improve the treatment of DLBCL, either as single agents or in combination, that exploit their synergy to overcome resistance. We review the key novel targets and therapeutics in the treatment of DLBCL, including immunomodulatory agents and immunotherapy.
authors: Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
authors: Neha
authors: N
authors: Mehta-Shah
authors: Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address: younes@mskcc.org.
authors: Anas
authors: A
authors: Younes
mesh_terms: D006801:Humans; D007167:Immunotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000378:metabolism; D058990:Molecular Targeted Therapy; D016328:NF-kappa B / Q000378:metabolism; D011947:Receptors, Antigen, B-Cell / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D016328:NF-kappa B; D011947:Receptors, Antigen, B-Cell